Dapsone long term side effects: topical vs oral risks

Last updated 2026-07-27

Is topical dapsone safe for long-term use on skin?

Yes, for most people. Topical dapsone gel (brand name Aczone, 5% and 7.5% formulations) is FDA-approved for acne vulgaris in patients as young as 9, and the approval trials ran 12 weeks, with open-label extension safety data collected out to 12 months ^[1]. The most common long-term complaints are dryness, mild peeling, and oiliness at the application site. That's it for most users. The bigger historical worry was hemolysis (red blood cell breakdown) in people with G6PD deficiency, since oral dapsone causes this reliably. But topical absorption is low. In the approval trials, the FDA noted that hemoglobin and reticulocyte changes in G6PD-deficient subjects using topical dapsone were "similar to those observed in G6PD normal subjects" ^[1]. That's a meaningfully different safety profile than the oral drug. It's also the main reason dermatologists don't require G6PD testing before prescribing the gel. Still, "low risk" isn't "zero risk." Package labeling for Aczone continues to note that methemoglobinemia and hemolytic anemia are theoretically possible with topical use, particularly if applied to broken skin or in unusually high amounts ^[1]. If you've been on it for months and notice unusual fatigue, pale skin, or shortness of breath, that's worth a call to your prescriber, not a wait-and-see. For readers who want the practical side of things, our Dapsone Rx dosage page covers how the gel is actually applied and how often.

What are the long-term side effects of oral dapsone?

Oral dapsone is a sulfone antibiotic used for leprosy (Hansen's disease), dermatitis herpetiformis, and some off-label dermatologic and autoimmune conditions. It is not an acne treatment, and long-term oral use carries risks that don't apply to the topical gel at all. The two most common issues, seen in nearly everyone on sustained oral therapy, are dose-related hemolysis and methemoglobinemia. The CDC's clinical guidance on dapsone for leprosy states that "hemolysis and methemoglobinemia... occur to some degree in most patients receiving dapsone" ^[2]. This isn't a rare side effect list item, it's close to universal at standard doses, and it's why oral dapsone therapy includes routine blood monitoring. Beyond the blood effects, long-term oral users face a real risk of peripheral neuropathy (numbness, weakness, sometimes motor loss in the hands and feet), which can develop after months to years of therapy and does not always fully reverse after stopping the drug. Chronic use has also been linked to hepatitis and cholestatic jaundice in case reports, and rarely to a nephrotic syndrome-like kidney picture. The scariest long-term risk isn't really "long-term" at all: dapsone hypersensitivity syndrome (DHS), a severe reaction that typically appears 2 to 6 weeks after starting the drug, featuring fever, rash, and organ involvement (usually liver). Case series report DHS mortality historically in the range of 9-12% when it occurs ^[3]. It's rare, but it's the reason clinicians watch new oral dapsone patients closely in the first month, more than at the one-year mark.

Why does oral dapsone require G6PD testing but topical doesn't?

Because oral dapsone's core mechanism of red blood cell damage depends on G6PD enzyme activity, and the drug reaches red blood cells at doses high enough to matter. G6PD (glucose-6-phosphate dehydrogenase) protects red cells from oxidative stress. People with G6PD deficiency, an X-linked genetic condition affecting an estimated 400 million people worldwide and roughly 1 in 10 African American men in the US, have red cells that break down fast under oxidative drugs like dapsone ^[4]. The FDA label and clinical pharmacology references are direct about this: G6PD deficiency screening is recommended before starting oral dapsone, because deficient patients are at risk for severe, sometimes life-threatening hemolytic anemia at standard doses ^[5]. This isn't a "nice to check" recommendation, it changes the treatment plan. Some clinicians still use oral dapsone in G6PD-deficient patients when there's no alternative, but at reduced doses with tighter monitoring. Topical dapsone doesn't carry this same screening requirement because systemic absorption through skin is low enough that the FDA trial data showed no meaningful hemolysis signal in G6PD-deficient users of the gel ^[1]. If your dermatologist has you on the topical gel, don't assume you need the same bloodwork someone on oral dapsone needs. Different formulation, different route into the body, different risk math.

What blood tests are needed before and during oral dapsone therapy?

Before starting: a G6PD screening test, a complete blood count (CBC) with baseline hemoglobin and reticulocyte count, and liver function tests. Some clinicians also check a baseline methemoglobin level if the patient has any cardiopulmonary disease, since methemoglobinemia reduces oxygen-carrying capacity and matters more in people with limited reserve. During therapy: CBC monitoring is typically done weekly for the first month, every two weeks for the second and third months, and then periodically (often every 3 to 4 months) for the duration of treatment, per dermatology and infectious disease treatment protocols for dapsone-based regimens ^{[2] [3]}. Liver function tests are usually rechecked at similar intervals, especially in the first two months when dapsone hypersensitivity syndrome is most likely to appear. This monitoring schedule is a real time and cost commitment. It's also non-negotiable if you're on oral dapsone long-term. Skipping bloodwork because you feel fine is a common and dangerous mistake, since early hemolysis and early DHS often don't have obvious symptoms until they're advanced.

What does dapsone hypersensitivity syndrome look like?

Dapsone hypersensitivity syndrome (DHS) usually starts 2 to 6 weeks after beginning oral therapy, with fever, a widespread skin rash (often morbilliform, sometimes exfoliative), and swollen lymph nodes. Liver involvement, showing up as jaundice or elevated liver enzymes, is the most common internal organ complication and the main driver of severe outcomes. DHS belongs to the same family as DRESS syndrome (drug reaction with eosinophilia and systemic symptoms), and it's why any fever or new rash in the first two months of oral dapsone therapy needs same-day medical attention, not a wait-and-see approach. Case series estimate DHS occurs in roughly 0.5% to 3.6% of patients on oral dapsone for leprosy, with reported mortality in affected patients historically around 9.9% in one commonly cited series, though modern supportive care likely improves on that figure ^[3]. Treatment is stopping the drug immediately and starting systemic corticosteroids, sometimes with additional immunosuppression for severe cases. There is no rechallenge, once someone has had DHS, oral dapsone is off the table for life.

Can dapsone cause anemia or affect blood counts long term?

With oral use, yes, reliably. Oral dapsone shortens red blood cell lifespan through oxidative hemolysis, and most patients on standard doses (100 mg/day for adults in leprosy regimens) show measurable drops in hemoglobin and rises in reticulocyte count within the first few weeks ^[2]. In G6PD-normal patients this is usually mild and doesn't require stopping treatment. In G6PD-deficient patients it can be severe enough to cause symptomatic anemia requiring transfusion or dose reduction. Methemoglobinemia is the other blood effect worth tracking long-term. Dapsone's metabolites oxidize hemoglobin's iron, reducing its oxygen-carrying capacity. Most patients run a low, asymptomatic methemoglobin level throughout treatment. Levels above roughly 10-15% can start to cause visible cyanosis, headache, and fatigue, and levels above 50-70% are life-threatening. This is a chronic, dose-dependent effect, not something that only shows up early, so it's part of ongoing monitoring, more than the first-month workup. With topical dapsone, this pathway is essentially a non-issue at typical use. The FDA trial data found hematologic parameters in gel users tracked closely with placebo users, including in G6PD-deficient subjects ^[1].

Does long-term dapsone cause nerve damage (peripheral neuropathy)?

It can, with oral use over months to years, though it's less common than the hematologic effects. Dapsone-induced peripheral neuropathy typically presents as a predominantly motor neuropathy, weakness in the hands and feet, sometimes with muscle wasting, rather than the sensory numbness/tingling pattern seen with some other neuropathy-causing drugs. It's been documented in case reports across leprosy, dermatitis herpetiformis, and other long-term oral dapsone indications. The mechanism isn't fully worked out, and there's no dose threshold that guarantees safety, though higher cumulative doses and longer treatment duration both raise risk. Recovery after stopping the drug is variable. Some patients improve substantially over months, others are left with residual weakness. This is one of the more likely reasons a prescriber will taper or stop long-term oral dapsone even in patients tolerating it well otherwise, watching for early grip weakness or foot drop before it progresses. There is no established peripheral neuropathy signal for topical dapsone at approved acne dosing. It hasn't shown up in the FDA trial safety data ^[1], and given how little of the drug reaches systemic circulation through skin, that's consistent with what you'd expect pharmacologically.

Is dapsone gel or dapsone pills used for acne, and does that change the risk?

Topical dapsone gel is the FDA-approved acne option. Oral dapsone is not FDA-approved for acne, full stop. If someone is being prescribed oral dapsone tablets for acne, that's an off-label use carrying oral dapsone's full risk profile (hemolysis, methemoglobinemia, DHS, neuropathy) for a condition that has better-studied, lower-risk alternatives. This distinction matters because "dapsone for acne" searches often surface both drugs interchangeably, and they are not interchangeable in risk. The topical gel's approval (Aczone 5% in 2005, reformulated as 7.5% once-daily in 2016) rests on trials specifically in acne patients showing modest but real improvement in inflammatory lesion counts over 12 weeks compared to vehicle gel ^[1]. Oral dapsone's acne data is thin, mostly older small studies or off-label clinical experience, not a body of trials that supports routine use. If your dermatologist recommends the gel, you're in FDA-approved, well-studied territory. If oral dapsone comes up for acne specifically, that's worth a direct question about why, and whether a topical retinoid, other topical antibiotic, or isotretinoin might be a better-supported option instead.

How is oral dapsone dosed, and does dose affect long-term risk?

Yes, oral dapsone's risks are strongly dose-dependent. Standard adult dosing for leprosy is 100 mg once daily, often alongside rifampicin and clofazimine per WHO multidrug therapy regimens ^[6]. Dermatologic uses (dermatitis herpetiformis, certain autoimmune blistering diseases) often use lower doses, sometimes starting at 25-50 mg daily and titrating based on response and tolerability. Higher doses increase hemolysis severity, methemoglobin levels, and likely neuropathy risk, though DHS doesn't clearly track with dose the same way. This is why dose titration and monitoring go together: a prescriber starting low and increasing slowly, with bloodwork at each step, catches problems before they become dangerous. Jumping straight to a full adult dose without titration is a recognized risk factor for early severe hemolysis in susceptible patients. For anyone managing an oral dapsone regimen under medical supervision, understanding the dosing schedule matters for spotting problems early. Related resources on dosing mechanics, including our Dapsone Rx dosage guide and Dapsone Rx dosage calculator, cover the practical side of titration, though any dose changes should go through your prescriber, not self-adjustment.

Topical vs oral dapsone: side-by-side long-term risk comparison

What symptoms mean I should stop dapsone and call my doctor?

For anyone on oral dapsone: unusual fatigue, pale skin, shortness of breath, or dark urine (signs of hemolysis); blue-gray skin discoloration, headache, or confusion (signs of methemoglobinemia); fever with a new rash, especially in the first 6 weeks (possible DHS); and new weakness or numbness in hands or feet (possible neuropathy). Any of these warrants same-day contact with the prescribing clinician, not a wait-until-next-appointment approach. For topical gel users: significant new fatigue or unusual bruising is still worth a call, even though it's uncommon, along with any signs of a true allergic reaction (hives, facial swelling, difficulty breathing) which would mean stopping the gel and seeking care immediately. The honest bottom line on long-term risk: topical dapsone's long-term safety data, drawn from FDA trials with extensions out to a year, looks reassuring for the vast majority of users ^{[1] [1]}. Oral dapsone's long-term risk profile is real, well-documented in CDC and clinical pharmacology sources, and requires active monitoring for as long as someone stays on it ^{[2] [3] [5]}. Anyone considering oral dapsone, for any indication, should go in expecting bloodwork, not a set-and-forget prescription. Dapsone Rx covers provider-reviewed information on dapsone therapy; we don't compound or dispense the medication ourselves. If you're evaluating oral dapsone for a diagnosed condition, work with a prescriber who orders G6PD testing up front and sets a monitoring schedule before you fill anything, through a licensed pharmacy partner equipped to counsel on the monitoring plan.

Frequently asked questions

Does topical dapsone (Aczone) require a G6PD test?

No. FDA trial data found that hematologic changes in G6PD-deficient patients using topical dapsone gel were similar to G6PD-normal patients, so routine G6PD screening isn't required before starting the gel, unlike oral dapsone where it's recommended ^[1][6].

Can dapsone gel cause anemia over time?

It's uncommon. FDA trial data showed hemoglobin and reticulocyte levels in topical dapsone users tracked closely with placebo, even in G6PD-deficient participants. Anemia is a much more established risk with oral dapsone, which causes measurable hemolysis in most patients at standard doses.

What is dapsone hypersensitivity syndrome and how common is it?

It's a severe drug reaction to oral dapsone involving fever, rash, and organ damage (usually liver), typically appearing 2-6 weeks after starting treatment. Case series estimate incidence around 0.5% to 3.6% in leprosy patients on oral dapsone, with historical mortality near 9.9% when it occurs.

Is oral dapsone FDA-approved for acne?

No. Only topical dapsone gel (Aczone 5% and 7.5%) is FDA-approved for acne. Oral dapsone tablets are approved for leprosy and dermatitis herpetiformis; using them for acne is off-label and carries oral dapsone's full risk profile without strong supporting acne trial data.

How often does someone on oral dapsone need blood tests?

Common protocols check CBC weekly for the first month, every two weeks through month three, then every 3-4 months long-term, alongside liver function tests, especially in the first two months when dapsone hypersensitivity syndrome risk is highest. Exact schedules vary by prescriber and indication.

What percentage of people have G6PD deficiency?

G6PD deficiency affects an estimated 400 million people worldwide and is especially common in people of African, Mediterranean, and Southeast Asian ancestry, including roughly 1 in 10 African American men in the US. It's the single biggest reason G6PD testing precedes oral dapsone therapy.

Does dapsone cause permanent nerve damage?

It can, with long-term oral use. Dapsone-induced peripheral neuropathy usually causes motor weakness in hands and feet after months to years of therapy. Recovery after stopping varies; some patients improve substantially, others retain residual weakness. This hasn't been established as a risk with topical acne gel.

Can you take oral dapsone if you're G6PD deficient?

Sometimes, under close supervision, at reduced doses with tighter monitoring, but it raises hemolysis risk substantially and many clinicians avoid it if alternatives exist. Screening before starting is the standard recommendation specifically to catch this and adjust the plan before treatment begins, not after symptoms appear.

What are the earliest warning signs of a problem on oral dapsone?

Fatigue, pale skin, or shortness of breath can signal hemolysis. Bluish skin, headache, or confusion can signal methemoglobinemia. Fever with a new rash in the first six weeks can signal dapsone hypersensitivity syndrome. Any of these means same-day contact with the prescribing clinician.

Is methemoglobinemia dangerous with long-term dapsone use?

It's usually mild and asymptomatic with oral dapsone at standard doses, but it's chronic and dose-dependent, meaning it doesn't just show up early and go away. Levels above roughly 10-15% can cause visible symptoms; levels above 50-70% are life-threatening, which is why ongoing monitoring matters, more than a first-month check.

How long can someone safely stay on oral dapsone?

There's no fixed cutoff; leprosy regimens often run 6-24 months per WHO multidrug therapy protocols, while dermatitis herpetiformis treatment can be long-term or lifelong depending on response. Duration is decided case by case based on ongoing bloodwork results and symptom monitoring, not a preset calendar.

Does dapsone gel have the same long-term risks as dapsone pills?

No, and this is the most important distinction to understand. Topical gel's systemic absorption is low, and FDA trial data shows a safety profile close to placebo for blood-related effects. Oral pills carry real, well-documented long-term risks including hemolysis, methemoglobinemia, neuropathy, and hypersensitivity syndrome.

Sources

1. FDA, Aczone (dapsone) gel 7.5% Prescribing Information: FDA trial data on topical dapsone gel safety, including G6PD-deficient subjects and hematologic parameters
2. CDC, Hansen's Disease (Leprosy) Clinical Care Guidance: Hemolysis and methemoglobinemia occur to some degree in most patients on oral dapsone
3. StatPearls (NCBI Bookshelf), Dapsone Toxicity: Incidence and mortality rates of dapsone hypersensitivity syndrome
4. CDC, Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: G6PD deficiency prevalence and affected populations
5. DailyMed, Dapsone Tablets, USP Prescribing Information (NLM): G6PD deficiency screening recommendation before oral dapsone therapy
6. World Health Organization, Guidelines for the Diagnosis, Treatment and Prevention of Leprosy: Standard oral dapsone multidrug therapy dosing for leprosy